Role of Growth Hormone in the Treatment of Postmenopausal Osteoporosis

  • John G. Haddad
Conference paper
Part of the Serono Symposia USA Norwell, Massachusetts book series (SERONOSYMP)

Abstract

Postmenopausal osteoporosis is a common disorder that can lead to acute and chronic morbidity, affecting many in the population (1, 2). Surely, prophylactic and therapeutic strategies that prevent or improve this condition are welcome. In recent years much attention has been paid to secondary osteoporosis (known disorders and medications or such influences as diet, activity, and alcohol that negatively influence the skeleton), as well as to agents that inhibit osteolysis (gonadal steroids, calcitonin [CT], and the bisphosphonate compounds) (3). Increasingly, however, agents associated with more robust bone formation, such as low-dose, intermittent parathyroid hormone (PTH), sodium fluoride, growth hormone (GH), and various growth factors, are being considered as potential additions to our therapeutic armamentarium.

Keywords

Estrogen Osteoporosis Adenoma Coherence Testosterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Riggs BL, Melton LJ. Involutional osteoporosis. N Eng J Med 1986; 314: 1676–86.CrossRefGoogle Scholar
  2. 2.
    Consensus conference: osteoporosis. JAMA 1984; 252:799–80.Google Scholar
  3. 3.
    Recker RR. Current therapy for osteoporosis. J Clin Endocrinol Metab 1993; 76: 14–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP. Impaired growth hormone secretion in the adult population. J Clin Invest 1981; 67: 1361–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Thorner MO, Vance ML, Horvath E, Kovacs K. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. 8th ed. Philadelphia: WB Saunders, 1992: 229–34.Google Scholar
  6. 6.
    Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985; 33: 800–7.PubMedGoogle Scholar
  7. 7.
    Parfitt AM. Growth hormone and adult bone remodeling. Clin Endocrinol (Oxf) 1991; 35: 467–70.CrossRefGoogle Scholar
  8. 8.
    Marcus, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant hGH to elderly people. J Clin Endocrinol Metab 1990; 70: 519–27.PubMedCrossRefGoogle Scholar
  9. 9.
    Bengtsson B, Eden S, Lonn L, et al. Treatment of adults with growth hormone deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Schlemmer A, Johansen J, Pedersen S, Jargensen J, Hassager C, Christiansen C. The effect of growth hormone (GH) therapy on urinary pyridinoline crosslinks in GH-deficient adults. Clin Endocrinol (Oxf) 1991; 35: 471–6.CrossRefGoogle Scholar
  11. 11.
    O’Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993; 76: 1344–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Shore RM, Chesney RW, Mazess RB, Rose PG, Bergman GJ. Bone mineral status in growth hormone deficiency. J Pediatr 1980; 96: 393–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Aloia JF, Roginsky MS, Jowsey J, Dombrowski CS, Shukla K, Cohn SH. Skeletal metabolism and body composition in acromegaly. J Clin Endocrinol Metab 1972; 35: 543–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Ezzat S, Melmed S, Endres D, Eyre DR, Singer F. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993; 76: 1452–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Seeman E, Wohner HW, Offord KP. Differential effects of endocrine dysfunction on the axial and appendicular skeleton. J Clin Invest 1982; 69: 1302–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 1989; 111: 567–73.PubMedGoogle Scholar
  17. 17.
    Aloia JF, Zanzi I, Ellis K, et al. Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 1976; 43: 992–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Aloia JF, Vasani A, Meunier P, et al. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin. Calcif Tissue Int 1987; 40: 253–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Aloia JF, Vawani A, Kapoor A, Yeh JK, Cohn SH. Treatment of osteoporosis with calcitonin with and without growth hormone. Metabolism 1985; 34: 124–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Eng J Med 1990; 323: 1–6.CrossRefGoogle Scholar
  21. 21.
    Martinez JA, DelBarrio AS, Larralde J. Evidence of a short term effect of growth hormone on in vivo bone protein synthesis in normal rats. BBA 1991; 1093: 111–3.PubMedGoogle Scholar
  22. 22.
    Harris WH, Heaney RP. Effect of growth hormone on skeletal mass in adult dogs. Nature 1969; 223: 403–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Mann DR, Rudman CG, Akinbami MA, Gould KG. Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration. J Clin Endocrinol Metab 1992; 74: 1263–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Mosekilde L, Bak B. The effects of growth hormone on fracture healing in rats: a histological description. Bone 1993; 14: 19–27.PubMedCrossRefGoogle Scholar
  25. 25.
    Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Neer R, Slovik D, Daly M, Lo C, Potts JT, Nussbaum S. Treatment of postmenopausal osteoporosis with daily PTH plus calcitriol. In: Christiansen C, Overgaard K, eds. Osteoporosis. Copenhagen: Osteopress ApS, 1990: 1314–7.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1995

Authors and Affiliations

  • John G. Haddad

There are no affiliations available

Personalised recommendations